Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 7
2005 2
2006 6
2007 3
2008 3
2009 3
2010 2
2011 3
2012 4
2013 3
2014 8
2015 7
2016 16
2017 12
2018 8
2019 9
2020 11
2021 8
2022 12
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Results by year

Filters applied: . Clear all
Page 1
Genetic ancestry and radical prostatectomy findings in Hispanic/Latino patients.
Acosta-Vega NL, Varela R, Mesa JA, Garai J, Gómez-Gutiérrez A, Serrano-Gómez SJ, Zabaleta J, Sanabria-Salas MC, Combita AL. Acosta-Vega NL, et al. Among authors: zabaleta j. Front Oncol. 2024 Apr 3;14:1338250. doi: 10.3389/fonc.2024.1338250. eCollection 2024. Front Oncol. 2024. PMID: 38634046 Free PMC article.
Tumor infiltrating lymphocytes (TILs) are a prognosis biomarker in Colombian patients with triple negative breast cancer.
Huertas-Caro CA, Ramírez MA, Rey-Vargas L, Bejarano-Rivera LM, Ballen DF, Nuñez M, Mejía JC, Sua-Villegas LF, Cock-Rada A, Zabaleta J, Fejerman L, Sanabria-Salas MC, Serrano-Gomez SJ. Huertas-Caro CA, et al. Among authors: zabaleta j. Sci Rep. 2023 Dec 3;13(1):21324. doi: 10.1038/s41598-023-48300-4. Sci Rep. 2023. PMID: 38044375 Free PMC article.
Sulindac sulfide as a non-immune suppressive γ-secretase modulator to target triple-negative breast cancer.
Hossain F, Ucar DA, Monticone G, Ran Y, Majumder S, Larter K, Luu H, Wyczechowska D, Heidari S, Xu K, Shanthalingam S, Matossian M, Xi Y, Burow M, Collins-Burow B, Del Valle L, Hicks C, Zabaleta J, Golde T, Osborne B, Miele L. Hossain F, et al. Among authors: zabaleta j. Front Immunol. 2023 Oct 13;14:1244159. doi: 10.3389/fimmu.2023.1244159. eCollection 2023. Front Immunol. 2023. PMID: 37901240 Free PMC article.
Evaluation of genetic alterations in hereditary cancer susceptibility genes in the Ashkenazi Jewish women community of Mexico.
Díaz-Velásquez CE, Gitler R, Antoniano A, Kershenovich Sefchovich R, De La Cruz-Montoya AH, Martínez-Gregorio H, Rojas-Jiménez EA, Cortez Cardoso Penha R, Terrazas LI, Wegman-Ostrosky T, Levi-Lahad E, Zabaleta J, Perdomo S, Vaca-Paniagua F. Díaz-Velásquez CE, et al. Among authors: zabaleta j. Front Genet. 2023 Feb 10;14:1094260. doi: 10.3389/fgene.2023.1094260. eCollection 2023. Front Genet. 2023. PMID: 36845387 Free PMC article.
Correction to: A combination of novel NSC small molecule inhibitor along with doxorubicin inhibits proliferation of triple-negative breast cancer through metabolic reprogramming.
Yousefi H, Khosla M, Lauterboeck L, Okpechi SC, Worthylake D, Garai J, Zabaleta J, Guidry J, Zarandi MA, Wyczechowska D, Jayawickramarajah J, Yang Q, Kissil J, Alahari SK. Yousefi H, et al. Among authors: zabaleta j. Oncogene. 2023 Mar;42(11):859. doi: 10.1038/s41388-023-02608-7. Oncogene. 2023. PMID: 36759576 No abstract available.
124 results